Ontario Airport Testing Site
Ontario Airport Testing Site
- Open Everyday 6:30AM - 10:30PM
Starting April 17th, Covid Clinic is proud to partner with Ontario Airport to provide testing for travelers to Hawaii!
Available tests include: “1 Day PCR COVID-19 Test” and “1 Hour COVID-19 Molecular NAAT Test”
Located in Lot 3.
This is a drive-through collection site. Patients can stay in the safety of their vehicle.
Tests Available At This Location
*Accepted by the state of Hawaii
Covid Clinic provides a $0 upfront service for COVID-19 PCR testing for eligible insured and uninsured patients. When patients pay out-of-pocket for testing they may be able to receive reimbursement from their health insurance provider for all or a portion of their COVID-19 test. Patients are invited to contact their insurance provider for additional information as to whether they may be eligible to receive reimbursement for a COVID-19 test and how to apply. Click Here to see an example of the invoice each patient receives for their test(s).
Rapid COVID-19 IgG/IgM Antibody Test
This test is used to detect COVID-19 antibodies. A positive antibody test result suggests the patient was recently infected by COVID-19 or has developed an immune response through vaccination.
Results are generally reported within 30 minutes at most locations.
Assure COVID-19 IgG/IgM Rapid Test Device
- IgG: This is the most common antibody. It’s in blood and other body fluids, and protects against bacterial and viral infections. IgG can take time to form after an infection or immunization.
- IgM: Found mainly in blood and lymph fluid, this is the first antibody the body makes when it fights a new infection.
The Assure COVID-19 IgG/IgM Rapid Test Device, a test for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 (often referred to as COVID-19 or the novel coronavirus) in human venous whole blood (sodium EDTA), serum, plasma (sodium EDTA) and fingerstick whole blood.
The Assure COVID-19 IgG/IgM Rapid Test Device is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity
September 23, 2020 and the FDA guidance, “Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency” issued on March 16, 2020 (updated May 11, 2020). The
- FDA issued this guidance to help accelerate the availability of novel coronavirus (COVID-19) tests developed by laboratories and commercial manufacturers during the public health emergency. This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by laboratories certified under CLIA, that meet requirements to perform waived, moderate or high complexity test;
- This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1),
unless the authorization is terminated or revoked sooner. - Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. The sensitivity of the EcoTest COVID-19 IgG/IgM Rapid Test Device early after infection is unknown. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status;
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
Rapid COVID-19 Antigen Test
This test is used to rapidly detect an active COVID-19 infection in a patient.
Results are generally reported within 30 minutes at most locations.
Covid Clinic utilizes multiple antigen tests in order to make antigen testing more accessible. The antigen test administered to the patient will be one of the following three tests, but Covid Clinic is unable to guarantee which of the tests will be utilized for a specific patient.
Quidel Corporation Sofia SARS Antigen FIA Test
Access Bio, Inc. CareStart COVID-19 Antigen Test
Luminostics, Inc. Clip COVID Rapid Antigen Test
Test Information
All of Covid Clinic’s antigen test offerings utilize tests that have received emergency use authorization from the FDA.
For Quidel’s Sofia SARS Antigen FIA Test and Luminostics Clip COVID Rapid Antigen Test, the specimen is collected by a lower nasal swab (anterior nares). The cotton swab does not need to be inserted far into the nose, and is rotated in a circle around the entire inside edge of each nostril at least three times. Results are generally available within 30 minutes and delivered to the patient via email (with the individual’s consent).
For Access Bio’s CareStart COVID-19 Antigen Test, the specimen is collected by a lower nasal swab (anterior nares). Results are generally available within 30 minutes and delivered to the patient via email (with the individual’s consent).
COVID-19 Antigen + Flu Combo Test
Three tests in one! This test is recommended for all individuals and especially those with symptoms.
Used to rapidly detect COVID-19, Influenza A, and Influenza B
Results are generally reported within 30 minutes
Test Information
Covid Clinic is offering the Quidel Corporation Sofia 2 FLU + SARS Antigen FIA Test. This test has received an emergency use authorization from the FDA.
The specimen is collected by a nasal swab. The cotton swab does not need to be inserted far into the nose, and is rotated in a circle around the entire inside edge of each nostril at least three times. Results are generally available within 30 minutes although result time may vary from location to location.
Rapid COVID-19 Molecular NAAT Test
This test is used to rapidly detect an active COVID-19 infection in a patient.
Results are generally reported within 1 hour
Abbott ID Now COVID-19 Assay
Test Information
Covid Clinic, Inc. is offering the Abbott ID Now COVID-19 Assay performed on the ID NOW Instrument. This test is a rapid molecular in vitro diagnostic test utilizing an isothermal nucleic acid amplification technology intended for the qualitative detection of nucleic acid from the SARS-CoV-2 viral RNA in direct nasal swabs. The ID Now COVID-19 Assay has received Emergency Use Authorization (EUA) from the FDA.
Many travel restrictions require a molecular or NAAT test be conducted prior to arrival. Abbott’s ID Now COVID-19 test may satisfy these requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase.
Rapid RT-PCR COVID-19 Test
Results are generally reported within one hour
Satisfies most travel restriction requirements
Collected by anterior nares nasal swab (front of the nose only)
Test Information
The Rapid RT-PCR COVID-19 Test is a molecular, in vitro diagnostic test utilizing end point reverse transcriptase polymerase chain reaction (RT-PCR) and lateral flow technologies for the qualitative, visual detection of the coronavirus SARS-CoV-2 viral RNA. The four steps utilized to perform the test are lysis of the virus, reverse transcription of viral RNA to cDNA, nucleic acid amplification, and detection.
The Rapid RT-PCR COVID-19 Test has been released under FDA Emergency Use Authorization (EUA) for the detection of nucleic acid from SARS-CoV-2 (the virus responsible for COVID-19 infection), and can be used in applications that require molecular/ RT-PCR testing. Please consult your state health department for additional information regarding specific uses (such as pre and post travel requirements). Many travel restrictions require a RT-PCR, molecular, or NAAT test be conducted prior to arrival at the destination. The Rapid RT-PCR COVID-19 test satisfies most travel requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase.
Expedited RT-PCR COVID-19 Test
Results are generally reported the next day by 11:59PM Pacific Time
Satisfies most travel restriction requirements
Can be collected by nasal mid-turbinate or nasopharyngeal swab.
One of the following tests will be utilitized for the Expedited RT-PCR COVID-19 Test:
DiaCarta QuantiVirus SARS-CoV-2 Multiplex Kit
Quidel Lyra Direct SARS-CoV-2 Assay
Bioeksen Bio-Speedy Direct RT-qPCR SARS-CoV-2
Test Information
The RT-PCR COVID-19 Test has been released under FDA Emergency Use Authorization (EUA) for the detection of nucleic acid from SARS-CoV-2 (the virus responsible for COVID-19 infection), and can be used in applications that require molecular/ RT-PCR testing. Please consult your state health department for additional information regarding specific uses (such as pre and post travel requirements). This test is an RT-PCR, molecular and NAAT test which satisfies most travel requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase. Please note that most travel restrictions require that a traveler’s test specimen IS COLLECTED within 72 hours prior to arrival at a destination.
Rapid COVID-19 IgG/IgM Antibody Test
This test is used to detect COVID-19 antibodies. A positive antibody test result suggests the patient was recently infected by COVID-19 or has developed an immune response through vaccination.
Results are generally reported within 30 minutes at most locations.
Assure COVID-19 IgG/IgM Rapid Test Device
- IgG: This is the most common antibody. It’s in blood and other body fluids, and protects against bacterial and viral infections. IgG can take time to form after an infection or immunization.
- IgM: Found mainly in blood and lymph fluid, this is the first antibody the body makes when it fights a new infection.
The Assure COVID-19 IgG/IgM Rapid Test Device, a test for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 (often referred to as COVID-19 or the novel coronavirus) in human venous whole blood (sodium EDTA), serum, plasma (sodium EDTA) and fingerstick whole blood.
The Assure COVID-19 IgG/IgM Rapid Test Device is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity
September 23, 2020 and the FDA guidance, “Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency” issued on March 16, 2020 (updated May 11, 2020). The
- FDA issued this guidance to help accelerate the availability of novel coronavirus (COVID-19) tests developed by laboratories and commercial manufacturers during the public health emergency. This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by laboratories certified under CLIA, that meet requirements to perform waived, moderate or high complexity test;
- This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1),
unless the authorization is terminated or revoked sooner. - Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. The sensitivity of the EcoTest COVID-19 IgG/IgM Rapid Test Device early after infection is unknown. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status;
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
Rapid COVID-19 Antigen Test
This test is used to rapidly detect an active COVID-19 infection in a patient.
Results are generally reported within 30 minutes at most locations.
Covid Clinic utilizes multiple antigen tests in order to make antigen testing more accessible. The antigen test administered to the patient will be one of the following three tests, but Covid Clinic is unable to guarantee which of the tests will be utilized for a specific patient.
Quidel Corporation Sofia SARS Antigen FIA Test
Access Bio, Inc. CareStart COVID-19 Antigen Test
Luminostics, Inc. Clip COVID Rapid Antigen Test
Test Information
All of Covid Clinic’s antigen test offerings utilize tests that have received emergency use authorization from the FDA.
For Quidel’s Sofia SARS Antigen FIA Test and Luminostics Clip COVID Rapid Antigen Test, the specimen is collected by a lower nasal swab (anterior nares). The cotton swab does not need to be inserted far into the nose, and is rotated in a circle around the entire inside edge of each nostril at least three times. Results are generally available within 30 minutes and delivered to the patient via email (with the individual’s consent).
For Access Bio’s CareStart COVID-19 Antigen Test, the specimen is collected by a lower nasal swab (anterior nares). Results are generally available within 30 minutes and delivered to the patient via email (with the individual’s consent).
COVID-19 Antigen + Flu Combo Test
Three tests in one! This test is recommended for all individuals and especially those with symptoms.
Used to rapidly detect COVID-19, Influenza A, and Influenza B
Results are generally reported within 30 minutes
Test Information
Covid Clinic is offering the Quidel Corporation Sofia 2 FLU + SARS Antigen FIA Test. This test has received an emergency use authorization from the FDA.
The specimen is collected by a nasal swab. The cotton swab does not need to be inserted far into the nose, and is rotated in a circle around the entire inside edge of each nostril at least three times. Results are generally available within 30 minutes although result time may vary from location to location.
Rapid COVID-19 Molecular NAAT Test
This test is used to rapidly detect an active COVID-19 infection in a patient.
Results are generally reported within 1 hour
Abbott ID Now COVID-19 Assay
Test Information
Covid Clinic, Inc. is offering the Abbott ID Now COVID-19 Assay performed on the ID NOW Instrument. This test is a rapid molecular in vitro diagnostic test utilizing an isothermal nucleic acid amplification technology intended for the qualitative detection of nucleic acid from the SARS-CoV-2 viral RNA in direct nasal swabs. The ID Now COVID-19 Assay has received Emergency Use Authorization (EUA) from the FDA.
Many travel restrictions require a molecular or NAAT test be conducted prior to arrival. Abbott’s ID Now COVID-19 test may satisfy these requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase.
Rapid RT-PCR COVID-19 Test
Results are generally reported within one hour
Satisfies most travel restriction requirements
Collected by anterior nares nasal swab (front of the nose only)
Test Information
The Rapid RT-PCR COVID-19 Test is a molecular, in vitro diagnostic test utilizing end point reverse transcriptase polymerase chain reaction (RT-PCR) and lateral flow technologies for the qualitative, visual detection of the coronavirus SARS-CoV-2 viral RNA. The four steps utilized to perform the test are lysis of the virus, reverse transcription of viral RNA to cDNA, nucleic acid amplification, and detection.
The Rapid RT-PCR COVID-19 Test has been released under FDA Emergency Use Authorization (EUA) for the detection of nucleic acid from SARS-CoV-2 (the virus responsible for COVID-19 infection), and can be used in applications that require molecular/ RT-PCR testing. Please consult your state health department for additional information regarding specific uses (such as pre and post travel requirements). Many travel restrictions require a RT-PCR, molecular, or NAAT test be conducted prior to arrival at the destination. The Rapid RT-PCR COVID-19 test satisfies most travel requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase.
Expedited RT-PCR COVID-19 Test
Results are generally reported the next day by 11:59PM Pacific Time
Satisfies most travel restriction requirements
Can be collected by nasal mid-turbinate or nasopharyngeal swab.
One of the following tests will be utilitized for the Expedited RT-PCR COVID-19 Test:
DiaCarta QuantiVirus SARS-CoV-2 Multiplex Kit
Quidel Lyra Direct SARS-CoV-2 Assay
Bioeksen Bio-Speedy Direct RT-qPCR SARS-CoV-2
Test Information
The RT-PCR COVID-19 Test has been released under FDA Emergency Use Authorization (EUA) for the detection of nucleic acid from SARS-CoV-2 (the virus responsible for COVID-19 infection), and can be used in applications that require molecular/ RT-PCR testing. Please consult your state health department for additional information regarding specific uses (such as pre and post travel requirements). This test is an RT-PCR, molecular and NAAT test which satisfies most travel requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase. Please note that most travel restrictions require that a traveler’s test specimen IS COLLECTED within 72 hours prior to arrival at a destination.
